Anticancer Effect of Metformin in Herceptin-Conjugated Liposome for Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ji-Yeon | - |
dc.contributor.author | Shin, Dae Hwan | - |
dc.contributor.author | Kim, Jin-Seok | - |
dc.date.available | 2021-02-22T05:35:52Z | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/2560 | - |
dc.description.abstract | Metformin (MET) is an anti-diabetic drug effective against breast cancer, targeting breast cancer stem cells (BCSCs). MET-encapsulating liposome (LP-MET) and Herceptin-conjugated LP-MET (Her-LP-MET) were evaluated for their anti-cancer effect in vitro and in vivo. Size and zeta potentials of LP-MET and Her-LP-MET were suitable for enhanced permeability and retention effects. Her-LP-MET yielded greater inhibition of BCSC proliferation in vitro than free MET or LP-MET, as well as a dose-dependent long-term anti-proliferation effect. Further, the anti-migration effect of Her-LP-MET on BCSCs was superior to that of MET or LP-MET, and was enhanced when used in concert with doxorubicin (DOX). In a mouse model, Her-LP-MET combined with free DOX was more effective than free MET, free DOX, or Her-LP-MET. Moreover, Her-LP-MET combined with free DOX yielded tumor remission, whereas free DOX alone resulted in metastasis or death. As such, Her-LP-MET formulation is expected to provide a new therapeutic modality targeting BCSCs. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Anticancer Effect of Metformin in Herceptin-Conjugated Liposome for Breast Cancer | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/pharmaceutics12010011 | - |
dc.identifier.scopusid | 2-s2.0-85077186737 | - |
dc.identifier.wosid | 000514655800010 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, v.12, no.1 | - |
dc.citation.title | PHARMACEUTICS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ACTIVATED PROTEIN-KINASE | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | ENCAPSULATED DOXORUBICIN | - |
dc.subject.keywordAuthor | Metformin | - |
dc.subject.keywordAuthor | Herceptin | - |
dc.subject.keywordAuthor | breast cancer stem cell | - |
dc.subject.keywordAuthor | liposome | - |
dc.subject.keywordAuthor | targeting | - |
dc.identifier.url | https://www.mdpi.com/1999-4923/12/1/11 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.